SCHEMBL3744047

SCHEMBL3744047

CCCCCc1ccccc1C(=O)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
ADRB2 P07550 1/20 0.66
BCAT2 O15382 1/20 0.60
CYP3A4 P08684 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP1A2 P05177 1/20 0.59
KDM4E B2RXH2 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
LMNA P02545 2/20 0.58
KDR P35968 1/20 0.55
TRPV1 Q8NER1 1/20 0.55
HTT P42858 4/20 0.55
HPGD P15428 3/20 0.55
MEN1 O00255 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 1/20 0.55
F2R P25116 1/20 0.53
SLC16A3 O15427 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6271944 0.95 ALDH1A1 (0.68) ALDH1A1ADRB2BCAT2CYP3A4CYP2C19
SCHEMBL5595491 0.89 ALDH1A1 (0.71) ALDH1A1ADRB2BCAT2CYP3A4CYP2C19
SCHEMBL30742579 0.85 TRPV1 (0.56) ALDH1A1ADRB2BCAT2CYP3A4CYP2C19
Propylformate SCHEMBL28300667 0.85 ALDH1A1 (0.49) ALDH1A1ADRB2BCAT2CYP3A4CYP2C19
SCHEMBL19259498 0.84 BCAT2 (0.72) ALDH1A1ADRB2BCAT2CYP3A4CYP2C19
SCHEMBL1545821 0.83 HTT (0.49) HTTSLC16A3
SCHEMBL15923268 0.83 HTT (0.49) ALDH1A1KDM4EHTTHPGDMEN1
SCHEMBL7589245 0.82 HTT (0.45) ALDH1A1ADRB2CYP3A4KDM4ESMN1; SMN2
SCHEMBL4433080 0.81 LIPG (0.51) HTTSLC16A3
SCHEMBL11039198 0.81 LIPG (0.51) ALDH1A1KDM4EHTTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133320-A1 PROCESS FOR PRODUCING AN OVERMOLDED PART IN AN INJECTION MOLDING APPARATUS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2024-06-27 WO disclosed
EP-3352964-B1 METHOD OF INJECTION MOLDING USING RIBS AND PRODUCT SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-12-06 EP disclosed
EP-3107730-B1 MULTILAYER SHEET, METHODS FOR MAKING THE SAME, AND ARTICLES COMPRISING THE MULTILAYER SHEET SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-11-15 EP disclosed
WO-2023119130-A1 MULTIWALL SHEET INCLUDING AN ACOUSTIC RESONATOR SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2023-06-29 WO disclosed
WO-2023119132-A1 MULTIMATERIAL SHEET SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2023-06-29 WO disclosed
EP-3224533-B1 ENCLOSURE WITH A CONDENSATION-RESISTANT INTERIOR SURFACE SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-04-05 EP disclosed
EP-2732107-B1 A MULTIWALL SHEET, METHODS OF MAKING, AND ARTICLES COMPRISING THE MULTIWALL SHEET SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-04-05 EP disclosed
US-11590829-B2 Functional interlayers for vehicle glazing systems TESLA, INC. (US) 2023-02-28 US disclosed
EP-3344432-B1 PROCESS FOR PRODUCING LONGER FIBERS IN INJECTION MOLDED SOLID PARTS BY DISSOLVING OF GAS DURING PLASTICIZING SABIC GLOBAL TECHNOLOGIES BV (NL) 2022-12-21 EP disclosed
CN-104870530-B Polymers, articles comprising polymers, and methods of making and using the same 沙伯基础全球科技有限公司 2022-09-16 CN disclosed
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
WO-2009009308-A1 A WINDOW SHADE AND A MULTI-LAYERED ARTICLE, AND METHODS OF MAKING THE SAME SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-01-15 WO disclosed
US-20080014446-A1 WINDOW SHADE AND A MULTI-LAYERED ARTICLE, AND METHODS OF MAKING THE SAME GENERAL ELECTRIC COMPANY (US) 2008-01-17 US disclosed
WO-2007114060-A1 POLYCARBONATE-HYDROGENATED POLYBUTADIENE COPOLYMER, METHOD FOR PRODUCING SAME, AND POLYCARBONATE RESIN COMPOSITION USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2007-10-11 WO disclosed
US-20060078743-A1 Window shade and a multi-layered article, and methods of making the same CITIBANK, N.A., AS COLLATERAL AGENT 2006-04-13 US disclosed
US-20050203237-A1 Biocidal compositions and methods of making thereof CITIBANK, N.A., AS COLLATERAL AGENT 2005-09-15 US disclosed
US-20050202100-A1 Biocidal compositions and methods of making thereof CITIBANK, N.A., AS COLLATERAL AGENT 2005-09-15 US disclosed
US-5780551-A UNSYMMETRICALLY PROTECTED; FROM ONE OR MORE CONJUGATED DIENE OR ALKENYLAROMATIC COMPOUND FMC CORPORATION (US) 1998-07-14 US disclosed
WO-1997016465-A1 TELECHELIC POLYMERS FROM MIXED INITIATOR FMC CORPORATION (US) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 ALDH1A1 204/4885ADRB2 518/4885BCAT2 234/4885
US-20050202100-A1 Biocidal compositions and methods of making thereof PIK3C3, PRKACG, PRKX ALDH1A1 695/4885ADRB2 4509/4885BCAT2 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.